8-K: Gain Therapeutics Receives Approval to Initiate Phase 1b Clinical Trial for Parkinson's Drug in Australia

Gain Therapeutics has announced the approval to begin a Phase 1b clinical trial in Australia for their lead drug candidate, GT-02287, targeting Parkinson's disease.

Summary

• Gain Therapeutics has received approval in Australia to start a Phase 1b clinical trial for their drug candidate GT-02287, which is aimed at treating Parkinson's disease.
• The trial will assess the safety and tolerability of GT-02287 over three months in patients with Parkinson's disease, including those with a GBA1 mutation.
• This Phase 1b trial follows a successful Phase 1 study in healthy volunteers where GT-02287 showed a favorable safety profile and significant target engagement, increasing glucocerebrosidase (GCase) activity by more than 50%.
• The company expects to complete enrollment for the trial in the spring of 2025, with data expected mid-2025.
• The Phase 1b trial will be conducted at seven sites across major metropolitan areas in Australia, all with experience in Parkinson's disease trials.
• The trial will use a dosage of 13.5 mg/kg/day of GT-02287 and will also measure pharmacokinetics, GCase modulation, and other biomarkers.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful progression of the drug candidate into a Phase 1b trial, the favorable safety profile demonstrated in the Phase 1 study, and the anticipation of further positive results. The company's management also expresses optimism about the potential of GT-02287.

Positives

• The company has successfully transitioned from preclinical to clinical stage development with the initiation of the Phase 1b trial.
• GT-02287 has demonstrated a favorable safety and tolerability profile in a Phase 1 study.
• The Phase 1 study showed significant target engagement of GT-02287, with a statistically significant increase in GCase activity of more than 50%.
• The company is working with local Parkinson's disease advocacy groups to support enrollment.
• The trial is being conducted at seven sites in Australia, all with experience in Parkinson's disease trials.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the development of product candidates and the timing of clinical trial results.
• Actual results could differ materially from those contained in the forward-looking statements.

Future Outlook

Gain Therapeutics anticipates advancing GT-02287 into Phase 2 trial preparation in 2025 following the results of the Phase 1b trial, expected mid-year 2025.

Management Comments

• Gene Mack, CFO and Interim CEO of Gain Therapeutics, stated that the initiation of the Phase 1b clinical trial is a fitting end to a transformative year for the company.
• Gene Mack also mentioned that they believe GT-02287 has the potential to slow or stop the progression of Parkinson's disease.
• Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, noted that there is eagerness from investigators and potential participants in Australia to partake in the study.

Industry Context

This announcement is significant as it marks the progression of Gain Therapeutics' lead drug candidate into a Phase 1b trial, indicating advancement in the development of treatments for Parkinson's disease, a condition with significant unmet medical need. The use of Australian sites for the trial is also notable, as historically, there have been limited clinical trials in Parkinson's disease in Australia.

Comparison to Industry Standards

• The Phase 1 study results showing a greater than 50% increase in GCase activity are promising and suggest a strong target engagement for GT-02287, which is a key factor in the development of effective therapies for Parkinson's disease.
• Other companies such as Denali Therapeutics and Biogen are also developing therapies for Parkinson's disease, but Gain's approach with an allosteric small molecule is unique and could offer a different mechanism of action.
• The use of biomarkers in the Phase 1b trial, such as GCase modulation and levels of GCase substrates, is in line with current industry standards for assessing the efficacy of new treatments for neurodegenerative diseases.
• The selection of trial sites in Australia, which have experience with Parkinson's disease trials, is a positive step to ensure the quality and reliability of the data.

Stakeholder Impact

• Shareholders may view this announcement positively as it represents progress in the company's clinical development program.
• Patients with Parkinson's disease and their families may be encouraged by the potential of a new treatment option.
• Employees of Gain Therapeutics may be motivated by the advancement of their lead drug candidate.
• The Michael J. Fox Foundation and The Silverstein Foundation, who have provided funding support, will be interested in the trial results.

Next Steps

• Complete enrollment for the Phase 1b clinical trial in the spring of 2025.
• Collect and analyze data from the Phase 1b trial, expected mid-2025.
• Prepare for Phase 2 trial of GT-02287 in 2025.

Key Dates

Keywords

Parkinson's disease, clinical trial, GT-02287, GBA1 mutation, allosteric small molecule, glucocerebrosidase, GCase, Phase 1b, biomarkers, neurodegenerative